Chemical Namebelumosudil
Dosage FormTablet (oral; 200mg)
Drug ClassKinase inhibitors
CompanyKadmon Pharmaceuticals
Approval Year2021


  • For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Document TitleYearSource
Rezurock (belumosudil) Prescribing Information.2021Kadmon Pharmaceuticals LLC, Warrendale, PA
Drug updated on 6/1/2023

More on this drug: Clinical Trials